Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis
Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri · 2025
Read Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis by Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12860166.txt.
Description
Mohamed Saad Sayed and co-authors pool studies of nirsevimab, a single-dose antibody shot that shields babies from RSV, a virus that fills infant lungs each winter. Trials had shown promise, but real-world proof was scattered. The team searched five databases through April 2025.
They pooled 26 studies covering 425,362 infants. The shot cut RSV chest infections by 63 in a hundred and hospital stays by 73. It also cut all-cause chest illness, ICU stays, and deaths. Results varied a lot across settings, which the authors flag. Even so, the pooled picture favors the shot as a strong shield for the youngest babies.
Catalog record
| CREATOR | Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |